Correction: Pharma Equity Group A/S - Årsrapport 2023
20 mars 2024 12h15 HE
|
Pharma Equity Group A/S
Correction: Adding Annual Report in xhtml-file zip-format Pharma Equity Group A/S - Årsrapport 2023 Dato: 20. marts 2024 Årets meddelelse nr.: 07 Pharma Equity Group A/S - Årsrapport...
Correction: Pharma Equity Group A/S - Annual Report 2023
20 mars 2024 12h15 HE
|
Pharma Equity Group A/S
Correction: Adding Annual Report in xhtml-file zip-format Pharma Equity Group A/S - Annual Report 2023 Date: March 20, 2024Announcement of the Year No.: 7 Pharma Equity Group A/S - Annual...
Pharma Equity Group A/S - Årsrapport 2023
20 mars 2024 03h58 HE
|
Pharma Equity Group A/S
Pharma Equity Group A/S - Årsrapport 2023 Dato: 20. marts 2024 Årets meddelelse nr.: 07 Pharma Equity Group A/S - Årsrapport 2023 - året i hovedtræk Bestyrelsen for Pharma Equity Group A/S har dags...
Pharma Equity Group A/S - Annual Report 2023
20 mars 2024 03h58 HE
|
Pharma Equity Group A/S
Pharma Equity Group A/S - Annual Report 2023 Date: March 20, 2024Announcement of the Year No.: 7 Pharma Equity Group A/S - Annual report 2023 - main features of the year Today, the Board of...
Pharma Equity Groups datterselskab (Reponex Pharmaceuticals A/S) har modtaget meddelelse fra Det Europæiske Patentkontor (EPO) om beslutningen om at tildele deres patent for lægemiddelsammensætninger til fremme af sårheling (RNX-022).
05 mars 2024 04h11 HE
|
Pharma Equity Group A/S
Pharma Equity Groups datterselskab (Reponex Pharmaceuticals A/S) har modtaget meddelelse fra Det Europæiske Patentkontor (EPO) om beslutningen om at tildele deres patent for lægemiddelsammensætninger...
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).
05 mars 2024 04h11 HE
|
Pharma Equity Group A/S
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for...
Tegning af konvertible lån fuldført
07 févr. 2024 07h38 HE
|
Pharma Equity Group A/S
7. februar 2024 Selskabsmeddelelse nr. 05 Tegning af konvertible lån fuldført Bestyrelsen i Pharma Equity Group besluttede den 7. februar 2024 at udstede konvertible lån i overensstemmelse...
Completion of subscription of convertible loans
07 févr. 2024 07h38 HE
|
Pharma Equity Group A/S
7 February 2024 Company Announcement No. 05 Completion of subscription of convertible loans On 7 February 2024 the Board of Directors in Pharma Equity Group decided to issue convertible...
Bestyrelsens beslutning om udstedelse af konvertible lån
07 févr. 2024 03h46 HE
|
Pharma Equity Group A/S
Bestyrelsens beslutning om udstedelse af konvertible lån 7. februar 2024Meddelelse nr. 04 Bestyrelsen i Pharma Equity Group har truffet beslutning om udstedelse af yderligere konvertible lån i...
The Board of Director's decision to issue convertible loans
07 févr. 2024 03h46 HE
|
Pharma Equity Group A/S
The Board of Director's decision to issue convertible loans 7 February 2024Company Announcement no. 04 The Board of Directors of Pharma Equity Group has decided on the issuance of additional...